ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial An open-label, multicentre, single arm study to assess the efficacy and safety of triptorelin 6-month formulation administered subcutaneously in participants with locally advanced and/or metastatic prostate cancer previously treated and castrated with a GnRH analogue
EudraCT number 2021-005719-29
Protocol number D-FR-52014-245
Sponsor Ipsen Pharma SAS,65, quai Georges Gorse ,Boulogne Billancourt,92100,France
Indications Oncology
Diagnosis prostate cancer
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2022
Date of approval by Institute (SÚKL) 9.6.2022
Date of approval by EC 26.8.2022
Date of initiation CT in ČR 3.1.2023
Date of ending CT in ČR
Sites Fakultní nemocnice u sv. Anny v Brně,Onkologicko-chirurgické oddělení,Pekařská 53,Brno,656 91
Fakultní nemocnice Olomouc,Onkologická klinika,I. P. Pavlova 185/6,Olomouc,779 00 (discontinued)
Všeobecná fakultní nemocnice v Praze,Urologická klinika VFN a 1. LF UK v Praze,Ke Karlovu 6,Praha 2,128 08

‹‹ Back to list